VANDA PHARMACEUTICALS INC. Short-term Lease, Cost
VANDA PHARMACEUTICALS INC. (VNDA) reported Short-term Lease, Cost of $451.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShortTermLeaseCost · last filed 2026-02-12
- VANDA PHARMACEUTICALS INC. short-term lease, cost for the quarter ending 2019-12-31 was $100.00K.
- VANDA PHARMACEUTICALS INC. short-term lease, cost for the quarter ending 2019-09-30 was $100.00K.
- VANDA PHARMACEUTICALS INC. short-term lease, cost for the quarter ending 2019-06-30 was $100.00K.
- VANDA PHARMACEUTICALS INC. short-term lease, cost for the quarter ending 2019-03-31 was $100.00K.
- VANDA PHARMACEUTICALS INC. short-term lease, cost for fiscal 2025 was $451.00K, a 5.87% increase from fiscal 2024.
- VANDA PHARMACEUTICALS INC. short-term lease, cost for fiscal 2024 was $426.00K, a 7.58% increase from fiscal 2023.
- VANDA PHARMACEUTICALS INC. short-term lease, cost for fiscal 2023 was $396.00K, a 1.80% increase from fiscal 2022.
- VANDA PHARMACEUTICALS INC. short-term lease, cost for fiscal 2022 was $389.00K, a 2.75% decline from fiscal 2021.
| Period end | Short-term Lease, Cost 3 month | Short-term Lease, Cost 6 month | Short-term Lease, Cost 9 month | Short-term Lease, Cost 12 month | Short-term Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $451.00K 10-K · filed 2026-02-12 | ||||
| 2024-12-31 | $426.00K 10-K · filed 2026-02-12 | ||||
| 2023-12-31 | $396.00K 10-K · filed 2026-02-12 | $400.00K 10-K · filed 2024-02-08 | |||
| 2022-12-31 | $389.00K 10-K · filed 2025-02-14 | $400.00K 10-K · filed 2023-02-09 | |||
| 2021-12-31 | $400.00K 10-K · filed 2024-02-08 | ||||
| 2020-12-31 | $400.00K 10-K · filed 2023-02-09 | ||||
| 2019-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $200.00K derived: sum of 2 quarters · filed 2022-02-24 | $300.00K derived: sum of 3 quarters · filed 2022-02-24 | $400.00K 10-K · filed 2022-02-24 | |
| 2019-09-30 | $100.00K 10-Q · filed 2019-11-07 | $200.00K derived: sum of 2 quarters · filed 2019-11-07 | $300.00K 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $100.00K 10-Q · filed 2019-08-01 | $200.00K 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $100.00K 10-Q · filed 2019-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |